Want to join the conversation?
$BAX 2Q15 Call: Our biggest milestone for both quarter and the year was the successful completion BioScience spinoff, resulting in the establishment of two leading global healthcare companies. Addressing our standalone cost structure is crucial to meet our goal with increasing earnings at a rate meaningfully faster than sales growth.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.